Discover 1 curated intelligence briefings related to this specific topic.
The transition from bespoke, lab-scale CAR-T production to industrial-grade biomanufacturing requires a fundamental rejection of centralized hubs. By integrating closed-loop automation and shifting toward allogeneic platforms, the industry can slash vein-to-vein times and reduce the prohibitive cost of personalized medicine.
